Show simple item record

dc.contributor.authorCuzick, J
dc.contributor.authorSestak, I
dc.contributor.authorBaum, M
dc.contributor.authorBuzdar, A
dc.contributor.authorHowell, Anthony
dc.contributor.authorDowsett, M
dc.contributor.authorForbes, J
dc.date.accessioned2011-02-05T12:07:57Z
dc.date.available2011-02-05T12:07:57Z
dc.date.issued2010-12
dc.identifier.citationEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. 2010, 11 (12):1135-41 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid21087898
dc.identifier.doi10.1016/S1470-2045(10)70257-6
dc.identifier.urihttp://hdl.handle.net/10541/121326
dc.description.abstractThe Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdministration, Oral
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshNeoplasm Staging
dc.subject.meshNitriles
dc.subject.meshPostmenopause
dc.subject.meshTamoxifen
dc.subject.meshTreatment Outcome
dc.subject.meshTriazoles
dc.titleEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK. j.cuzick@qmul.ac.uken
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractThe Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.


Files in this item

This item appears in the following Collection(s)

Show simple item record